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ABSTRACT
Background: Non-steroidal anti-inflammatory drugs (NSAIDs), especially aspirin, and food additives (FAs)
may exacerbate allergic symptoms in patients with chronic idiopathic urticaria and food-dependent exercise-
induced anaphylaxis (FDEIA). Augmentation of histamine release from human mast cells and basophils by
those substances is speculated to be the cause of exacerbated allergic symptoms. We sought to investigate
the mechanism of action of aspirin on IgE-mediated histamine release.
Methods: The effects of NSAIDs, FAs or cyclooxygenase (COX) inhibitors on histamine release from human
basophils concentrated by gravity separation were evaluated.
Results: Benzoate and tartrazine, which have no COX inhibitory activity, augmented histamine release from
basophils similar to aspirin. In contrast, ibuprofen, meloxicam, FR122047 and NS-398, which have COX inhibi-
tory activity, did not affect histamine release. These results indicate that the augmentation of histamine release
by aspirin is not due to COX inhibition. It was observed that aspirin augmented histamine release from human
basophils only when specifically activated by anti-IgE antibodies, but not by A23187 or formyl-methionyl-leucyl-
phenylalanine. When the IgE receptor signaling pathway was activated, aspirin increased the phosphorylation
of Syk. Moreover, patients with chronic urticaria and FDEIA tended to be more sensitive to aspirin as regards
the augmentation of histamine release, compared with healthy controls.
Conclusions: Aspirin enhanced histamine release from basophils via increased Syk kinase activation, and
that the augmentation of histamine release by NSAIDs or FAs may be one possible cause of worsening symp-
toms in patients with chronic urticaria and FDEIA.
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INTRODUCTION
Aspirin, also known as acetylsalicylic acid, is widely
used as an antipyretic, pain reliever, anti-inflamma-
tory agent, and anticoagulant in a variety of diseases.
It reduces the formation of prostaglandins and
thromboxanes from arachidonic acid by inhibiting cy-
clooxygenases (COX)-1 and COX-2. COX-1 is respon-
sible for the physiological production of prostagland-
ins whereas COX-2 is involved in the increased pro-
duction of prostaglandins in inflammatory tissues.1
Adverse effects such as gastrointestinal disorders
often occur due to the inhibition of COX-1.2
Aspirin hypersensitivity, also known as aspirin in-
tolerance, can be categorized in three types by their
clinical presentations: i) aspirin-induced rhinitis and
asthma or aspirin-exacerbated respiratory tract dis-
ease (AERD) of which the main symptoms are bron-
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chospasm, rhinorrhea, conjunctivitis andor flushing;
ii) aspirin-induced urticaria andor angioedema; and
iii) a combination of i) and ii).3 Aspirin is also an ag-
gravating factor in chronic idiopathic urticaria. Ap-
proximately 20 to 30% of patients with chronic urti-
caria react adversely to aspirin.4 The mechanism of
aspirin hypersensitivity is not fully understood, but
decreased prostaglandin (PG) E2 levels due to COX-1
inhibition and increased production of cysteinyl leu-
kotrienes (TLs), LTC4, LTD4, and LTE4 are thought
to be the underlying mechanisms of AERD patho-
genesis.5 However, the pathogenesis of aspirin-
induced urticariaangioedema may be different from
that of AERD. Decreased levels of PGE2 andor
PGD2, which decrease histamine release from mast
cells, may be more important in the development of
symptoms than an increase in LTs.6
Food-dependent exercise-induced anaphylaxis
(FDEIA) is a particular form of food allergy. In
FDEIA, allergic symptoms such as urticaria and ana-
phylaxis are induced by physical exercise after inges-
tion of specific food.7,8 It has been reported that aspi-
rin may both augment the allergic symptoms and in-
duce allergic reactions without exercise in patients
with FDEIA.9,10 Previously, we demonstrated that as-
pirin increased the level of a blood antigen that corre-
lated with clinical symptoms.11,12 This finding indi-
cated that aspirin might facilitate allergen absorption
through a gastrointestinal disorder. However, the ad-
ministration of aspirin enhanced the reaction against
an allergen in a prick test for patients with FDEIA, in-
dicating that aspirin may also directly augment the
degranulation of mast cells.13 Interestingly, the
antigen-specific histamine release from antigen-
induced peripheral basophils was augmented by aspi-
rin in patients with pollen allergy.14 However, the cel-
lular and molecular mechanisms of augmentation of
histamine release by aspirin remain unclear. More-
over, food additives (FAs), such as tartrazine and
benzoate, augment histamine release from baso-
phils14 and may also trigger allergic symptoms simi-
lar to aspirin, although there is no clear evidence for
this.15 The aim of this study is to evaluate the aug-
mentation of histamine release by non-steroidal anti-
inflammatory drugs (NSAIDs) and FAs and investi-
gate its mechanism of action.
METHODS
REAGENTS AND MATERIALS
The following reagents were purchased: aspirin,
mepirizole (1-(4-Methoxy-6-methyl-2-pyrimidinyl)-3-
methyl-5-methoxy-1H-pyrazole), sunset yellow (5-[4-
(Sodiooxysulfonyl)phenylazo]-6-hydroxynaphthalene-
2-sulfonic acid sodium salt), Borudeaux S (1-(4-Sulfo-
1-naphthylazo)-2-hydroxy-3,6-naphthalenedisulfonic
acid trisodium salt), new coccine (2’-Hydroxy-[1,1’-
azobisnaphthalene]-4,6’,8’-trisulfonic acid trisodium
salt) (Wako Pure Chemical Industries, Osaka, Japan);
A23187, formyl-methionyl-leucyl-phenylalanine (fMLP),
thapsigargin, indomethacin, ibuprofen, sodium sali-
cylate, benzoate, ethyl p-hydroxy benzoate, tar-
trazine, PGE2 and PGD2 (Nakalai Tesque Inc.,
Kyoto, Japan); diclofenac, ketoprofen, mefenamic
acid, meloxicam, etodolac, and acetaminophen
(Sigma-Aldrich, MO, USA); anti-phospho-Syk (Tyr
352) antibody (Cell Signaling Technology, MA, USA);
anti-Syk antibody (Santa Cruz, CA, USA); FR122047
and SC-791 (Merck, Darmstadt, Germany); goat anti-
human IgE antibodies (Bethyl Laboratories, Mont-
gomery, TX, USA); HRP conjugated goat anti-rabbit
IgG (Biosource, CA, USA).
HISTAMINE RELEASE ASSAY
This study was approved by the ethics committee at
Hiroshima University. Sixteen chronic urticarial pa-
tients (3 males, 13 females, mean age: 43.3 years,
range: 14-81), 11 patients with FDEIA (5 males, 6 fe-
males, mean age: 33.1 years, range: 8-55), and 10
healthy controls (5 males, 5 females, mean age: 22.3
years, range: 20-38) were enrolled. Venous blood was
obtained from healthy adult volunteers who had
given informed consent. Peripheral blood leukocytes
containing approximately 1% basophils were prepared
as described by Tanaka et al.,16 with slight modifica-
tions. Briefly, heparinized peripheral blood was
mixed with 1% methylcellulose in saline and the solu-
tion was settled for 40 min at room temperature. After
centrifugation of the leukocyte-rich upper layer at 450
g for 15 min, the cell pellets were washed twice in
buffer A (137 mM NaCl, 5 mM glucose, 2.7 mM KCl,
0.4 mM NaH2PO4, 10 mM 4-(2-hydroxyethyl)-1-pipe-
razineethanesulfonic acid, 0.03% human serum albu-
min). The intact leukocytes were then resuspended
in 100 μl buffer A containing 2 mM CaCl2 and 1 mM
MgCl2. Once the crystalline compounds of NSAIDs,
FAs and COX inhibitors were dissolved in methanol
and air-dried in order to make them amorphous. The
amorphous form of compounds were redissolved
with buffer A containing 2 mM CaCl2 and 1 mM
MgCl2 then this chemical solution and a stimulant
such as goat anti-human IgE antibodies, A23187,
fMLP or thapsigargin dissolved in the same buffer
were added to the basophil suspension simultane-
ously. After incubation for 40 min at 37℃, the reac-
tions were terminated by the addition of 800 μl of ice-
cold buffer A and centrifugation at 2000 g for 5 min at
4℃. The supernatants were moved to new tubes and
the cell pellets were resuspended with 900 μl of
buffer A. Next, 100 μl aliquots of 20% HClO4 were
added to the supernatants and cell suspensions. After
centrifugation of these samples, the amounts of hista-
mine were measured by HPLC using a Shim-pack VP-
ODS column (4.6 × 150 mm; Shimadzu, Kyoto, Ja-
pan). A 20 μl aliquot of each sample solution was
loaded onto the HPLC. Histamine was eluted with
100 mM sodium tartrate buffer (pH 4.4) containing 10
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mM sodium 1-octane sulfonate and methanol (2.5 : 1
volvol) at a flow rate of 1.0 mlmin and a column
temperature of 50℃. The column eluent was mixed
with the derivatization reagent [400 mM sodium bo-
rate buffer (pH 9.2) and 10 mM o-phthalaldehyde in
methanol (2 : 1 volvol)], which was delivered by a
pump at a flow rate of 0.5 mlmin. The mixture was
passed through a reaction coil at 50℃ and the efflu-
ent was monitored fluorometrically (excitation: 360
nm; emission: 440 nm). Net histamine release was
calculated as a percentage of the total amount of his-
tamine in the cells after subtraction of spontaneous
release.
BASOPHIL PURIFICATION
Ethylenediaminetetraacetic acid-treated whole blood
was mixed with an equal amount of 2 mM EDTA in
phosphate-buffered saline (PBS). The mixture was
layered onto Ficoll-Paque PLUS (GE Healthcare,
Buckinghamshire, UK) and centrifuged at 400 g for
30 min. The buffy coats were isolated and basophils
were purified by means of magnetic bead sorting us-
ing a human basophil isolation kit II (MACS, Miltenyi
Biotech, Bergisch Gladbach, Germany) according to
the manufacture’s protocol.
DETECTION OF Syk PHOSPHORYLATION
Syk and phospho-Syk were detected with anti-Syk
and anti-phospho-Syk antibodies. The basophils puri-
fied from 56 ml venous blood (2.3-4.0 × 105 cells)
were suspended in buffer A containing 2 mM CaCl2
and 1 mM MgCl2, and incubated with goat anti-
human IgE antibodies in 200 μl per tube. After incu-
bation for 10 min at 37℃, the reactions were stopped
by adding ice-cold buffer A and centrifuged at 2000 g
for 5 min at 4℃. The supernatants were moved to
new tubes and the concentrations of histamine were
measured. The cell pellets were immediately lysed in
buffer for sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) and boiled. After elec-
trophoresis, proteins were transferred to a polyvi-
nylidene difluoride membrane (Immobilon-P, Milli-
pore, MA, USA). The membrane was blocked with
Tris-buffered saline pH 7.4 (TBS) containing 5%
skimmed milk, and was incubated with or without 1 :
1000 diluted anti-phospho-Syk antibodies at 4℃ over-
night. The membrane was washed 3 times with TBS
containing 1% Tween-20 (TBST), and incubated at
room temperature for 1 h with 1 : 10,000 diluted HRP-
labeled anti-rabbit IgG antibody (Biosource). The
membrane was washed 3 times with TBST, and pro-
teins bound to IgG were detected using an ECL-plus
western blot detection reagent (GE Healthcare) and
LAS-3000 imager (Fujifilm, Tokyo, Japan).
STATISTICAL ANALYSIS
Tukey’s and Dunnett’s test were used for statistical
analysis. The statistical analyses were performed with
PRISM (GraphPad, CA, USA).
RESULTS
HISTAMINE RELEASE FROM HUMAN BASO-
PHILS IN THE PRESENCE OF ASPIRIN
We first evaluated the augmentation of histamine re-
lease from peripheral basophils treated with various
concentrations of aspirin. The histamine release from
basophils was enhanced most strongly by 1000 μM of
aspirin and aspirin alone induced marginal histamine
release even at high concentration (Fig. 1a). A bell-
shaped anti-IgE dose-response of histamine release
was observed (Fig. 1b). Aspirin (1000 μM) aug-
mented the histamine release at all concentrations of
anti-human IgE used. Aspirin inactivates COX by act-
ing as an acetylating agent and an acetyl group binds
covalently to a serine residue in the active site of
COX. To ensure the inactivation of COX by aspirin,
basophils were preincubated with 1000 μM aspirin for
30 min before stimulation with anti-IgE. A similar
augmentation of histamine release was observed in
this experiment, but spontaneous histamine release
by preincubation with the buffer alone increased
(Fig. 1c). Therefore, 42 ngml of anti-human IgE was
used for stimulation of basophils, and basophils were
not preincubated with tested compounds in subse-
quent experiments.
The effects of aspirin on histamine release from ba-
sophils were evaluated in 10 healthy subjects (Fig. 1
d). Subject 8 was a non-responder to anti-IgE stimu-
lus. Aspirin (1000 μM) significantly increased the re-
lease of histamine induced by anti-IgE antibodies
from basophils of 7 of 9 responders. Basophils from
the other two subjects, 7 and 10, showed an increas-
ing tendency towards histamine release in the pres-
ence of 1000 μM aspirin. In contrast, 100 μM of aspi-
rin did not show any apparent effects on histamine re-
lease from basophils of any subjects.
EFFECTS OF NSAIDs AND FAs ON HISTAMINE
RELEASE
The effects of NSAIDs and FAs on histamine release
by anti-IgE stimuli are shown in Figure 2. Because
NSAIDs or FAs alone induced less than 5% of hista-
mine release even at high concentration of 1000 μM,
we calculated the percent of histamine release by
subtraction the quantity of histamine released by
chemical alone from that by anti-IgE with the chemi-
cal. Increased histamine secretion was observed in
the presence of aspirin, mefenamic acid, diclofenac,
etodolac, ketoprofen, benzoate and tartrazine. How-
ever, the effects of diclofenac and tartrazine were lost
or decreased at a dose of 1000 μM, whereas in-
domethacin inhibited histamine release at 1000 μM in
spite of the enhancement of histamine release at 10
μM. Ethyl p-hydroxy benzoate, Borudeaux S and sun-
set yellow also inhibited histamine release at a con-
centration of 1000 μM. Ibuprofen, meloxicam, mepiri-
Matsuo H et al.
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Fig.　1　The effect of aspirin on anti-human IgE induced histamine release from peripheral basophils. Dose-depen-
dency of aspirin (a) and anti-human IgE (b) on histamine release from basophils of healthy subject #1 and the effect 
of preincubation with aspirin for 30 min before stimulation (c). The augmentation of histamine release by 100 and 
1000 μM aspirin in 10 healthy subjects (d). Peripheral leukocytes were incubated with anti-human IgE antibodies in 
the presence or absence of aspirin for 40 min (a, b, d), or after basophils were preincubated with aspirin for 30 min 
anti-human IgE antibodies were added (c). *P < 0.05, **P < 0.01 compared with controls.
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zole, acetaminophen and new coccine had no effects
on histamine release in the presence or absence of
anti-IgE.
EFFECTS OF COX-1 AND COX-2 SELECTIVE IN-
HIBITORS AND PGEs ON HISTAMINE RELEASE
The effects of FR122047 and SC-791, cell-permeable
COX-1 and COX-2 selective inhibitors respectively,
and PGE2 and PGD2, on histamine release induced
by anti-IgE antibodies were examined. FR122047
(IC50 for human recombinant COX-1 and COX-2 is 28
nM and 65 μM, respectively)17 did not affect hista-
mine release from basophils at any concentration
tested. SC-791 did not affect histamine release at
doses between 0.1 to 10 μM, but augmented at a dose
of 100 μM (Fig. 3a, b). As the IC50 of SC-791 for COX-
1 and COX-2 is 114 μM and 4 nM, respectively,18 the
inhibition of COX was not related to the augmenta-
tion of histamine release. PGE2 and PGD2, derived
from arachidonic acid by COX, are known to inhibit
histamine release from human basophils, mouse
bone marrow derived mast cells, and rat peritoneal
mast cells.19,20 Histamine release from human baso-
phils by anti-IgE was inhibited by PGE2 in a dose de-
pendent manner in either the presence or absence of
aspirin (Fig. 3c). On the contrary, PGD2 did not af-
fect histamine release (Fig. 3d). On the other hand,
the augmentation of histamine release by aspirin was
remained at any concentration of PGE2 or PGD2.
ASPIRIN INHIBITED HISTAMINE RELEASE IN-
DUCED BY A23187, fMLP, AND THAPSIGARGIN
A23187, fMLP, and thapsigargin also induce hista-
mine release from basophils and mast cells by differ-
ent mechanisms from anti-IgE21: A23187 directly acti-
vates signaling pathways downstream of Ca2+ mobili-
zation; fMLP activates a G protein-coupled receptor
pathway; and thapsigargin induces Ca2+ influx by de-
pletion of intracellular Ca2+ stores. In contrast to aspi-
rin augmented IgE-mediated histamine release, 1000
μM of aspirin inhibited histamine release induced by
A23187, fMLP, and thapsigargin (Fig. 4).
ASPIRIN ENHANCED SYK PHOSPHORYLATION
Syk tyrosine kinase plays a pivotal role in IgE-
mediated histamine release from basophils. To ana-
lyze the phosphorylation of Syk and rule out the in-
volvement of leukocytes other than basophils in the
action of aspirin, we first confirmed that aspirin aug-
mented the histamine release in purified basophils
from three healthy donors (data not shown). Based
on a report by Gibbs et al.22 that phosphorylation of
Aspirin Augments IgE-Mediated Histamine Release
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Fig.　2　Effects of NSAIDs on histamine release from human basophils. Peripheral leukocytes from 
subject 1 were incubated with anti-human IgE antibodies (42 ng/ml) and NSAIDs for 40 min. The 
percent values of histamine release were calculated by subtraction the quantity of histamine re-
leased by chemicals alone from that by chemicals and anti-IgE antibodies. The histamine release 
by chemicals alone at 1000 μM were as follows: aspirin; 3.05 ± 0.74 (%), salicylate; 2.52 ± 0.59, 
mefenamic acid; 2.57 ± 0.28, diclofenac; 3.08 ± 0.41, indomethacin; 0.89 ± 0.16, etodolac; 1.88 ± 
0.43, ibuprofen; 2.54 ± 1.19, ketoprofen; 1.82 ± 0.35, meloxicam; 1.18 ± 0.20, mepirizole; 0.97 ± 
0.25, acetaminophen; 2.64 ± 0.33, benzoate; 2.36 ± 1.56, ethyl p-hydroxy benzoate; 2.09 ± 0.22, 
new coccine; 2.93 ± 1.36, borudeaux S; 0.57 ± 0.23, sunset yellow; 1.47 ± 0.33, tartrazine; 2.57 ± 
2.34. *P < 0.05, **P < 0.01 compared with controls.
0
50
100
150
200
250
A
sp
iri
n
S
al
ic
yl
at
e
M
ef
en
am
ic
 a
ci
d
D
ic
lo
fe
na
c
In
do
m
et
ha
ci
n
E
to
do
la
c
Ib
up
ro
fe
n
K
et
op
ro
fe
n
M
el
ox
ic
am
M
ep
iri
zo
le
A
ce
ta
m
in
op
he
n
B
en
zo
at
e
E
th
yl
 p
-h
yd
ro
xy
   
be
nz
oa
te
N
ew
 c
oc
ci
ne
B
or
ud
ea
ux
 S
S
un
se
t y
el
lo
w
T
ar
tr
az
in
e
0 10 100 1000 (PM)
H
is
ta
m
in
e 
re
le
as
e 
(%
 o
f c
on
tr
ol
)
**
**
**
**
**
** ** **
** **
**
*
*
* *
*
Syk is sustained for 10 minutes after stimulation by
anti-human IgE antibodies, we examined the effect of
aspirin on Syk phosphorylation in basophils stimu-
lated by anti-IgE antibodies for 10 minutes in the
presence or absence of 1000 μM aspirin. The phos-
phorylation of Syk was determined by anti-phospho
Syk Tyr 352 antibodies. The presence of 1000 μM as-
pirin markedly increased Syk phosphorylation in-
duced by anti-IgE antibodies (Fig. 5).
ASPIRIN SENSITIVITY OF IgE MEDIATED HISTA-
MINE RELEASE FROM BASOPHILS OF PA-
TIENTS WITH CHRONIC URTICARIA AND FDEIA
Histamine release tests with anti-human IgE were
conducted in 16 patients with chronic urticaria, 11 pa-
tients with FDEIA, and 10 healthy controls. Data
from ten patients and one healthy control whose his-
tamine release by anti-IgE were less than 10%
(classed as non-responders) were excluded from the
study. Addition of 1000 μM aspirin augmented hista-
mine release more than 10% in 14 of 17 patients
(82.4%) and in 8 of 9 healthy controls (88.9%) (Fig. 6).
A dose of 100 μM aspirin augmented histamine re-
lease from basophils of seven patients and only one
healthy control (11.1%).
DISCUSSION
In this study, we demonstrated that aspirin aug-
mented histamine release from human basophils and
specifically activated the IgE receptor signaling path-
way. The FAs, benzoate and tartrazine, also aug-
mented histamine release from human basophils,
suggesting that augmentation of histamine release by
aspirin is not due to inhibition of COX. Moreover, our
results indicate that patients with chronic urticarial
and FDEIA tend to be more sensitive to aspirin in the
augmentation of histamine release.
Wojnar et al.14 reported that aspirin (917 μM), di-
clofenac (51 μM), ketoprofen (375 μM), indometha-
cin (0.1 μM), mefenamic acid (35 μM), salicylate (120
μM), and tartrazine (1.7 mM) augmented histamine
release by 25% in human basophils. Our data were al-
most in accordance with their results. They specu-
lated that suppression of PG production by a number
of drugs was one mechanism for the augmentation of
histamine release as NSAIDs inhibit COX, a key en-
zyme for prostaglandin production. It has been
shown that PGE2 can reduce histamine release from
human lung mast cells and basophils.20 However, we
found that neither ibuprofen nor FR122047, cell mem-
brane permeable COX-1 selective inhibitors, affected
histamine release. Moreover, benzoate and tar-
trazine, which have no COX inhibitory activity, en-
hanced histamine release. These results indicate that
there is no correlation between inhibition of COX and
an increase of basophil degranulation activity. The ad-
Matsuo H et al.
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Fig.　3　Effect of cell-permeable COX-1 and -2 selective inhibitors (a, b) and PGs (c, d) on 
histamine release from basophils by anti-IgE antibodies. COX inhibitors, aspirin and PGs 
were co-incubated with anti-IgE and incubated for 40 min. *P < 0.05, **P < 0.01.
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Fig.　5　Aspirin upregulates anti-IgE-stimulated phosphorylation of Syk kinase in purifi ed 
basophils. Basophils purifi ed from venous blood were incubated with anti-IgE in the pres-
ence or absence of aspirin for 10 min at 37°C. The reactions were stopped and the cell 
pellets were immediately lysed in buffer for sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) and boiled. Proteins were then transferred to a polyvinylidene 
difl uoride membrane and phospho-Syk was detected by anti-phospho-Syk (Tyr 352) anti-
body. Reblotting with anti-Syk antibody verifi ed equal protein loading between samples (a). 
Three experiments were carried out using basophils from three healthy subjects (one ex-
periment in each donor). Bands in western blot were quantitated by image analysis and the 
mean relative intensity of the band was calculated (b). *P < 0.05.
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dition of PGE2 to the reaction mixture did not inhibit
the enhancement of histamine release induced by as-
pirin (Fig. 3c). Therefore, there is likely another
mechanism involved in the augmentation of hista-
mine release by aspirin other than decreasing PG
production due to COX inhibition.
Most NSAIDs and FAs that augmented the hista-
mine release from basophils by anti-IgE antibodies in
this study were acidic compounds. It seems likely
that high concentration of acidic chemical enhanced
histamine release. To eliminate that possibility we
demonstrated that the acetic acid, one of the simplest
carboxylic acids, has no effect on the augmentation of
histamine release (data not shown). In addition to
carboxylic acid residue the active chemicals have
benzene ring in their structure indicating that those
structures could be important to show the augmenta-
tion of histamine release.
The high affinity IgE receptor (FcεRI) is a te-
trameric complex consisting of an α-chain, a β-chain,
and two γ-chains. Binding of an allergen to two IgE
molecules attached to the extra cellular domain of α-
chains, causes phosphorylation of Syk kinase and
eventually diacylglycerol and inositol 1,4,5-trispho-
sphate (derived from phosphatidylinositol 4,5-bis-
phospate by phospholipase Cγ) induce calcium influx
into cells leading to degranulation of basophils. Intra-
cellular FcεRI receptor signaling progresses through
signaling and adaptor molecules such as Lyn, Syk, PI
3K, LAT and phospholipase Cγ.23 Apart from anti-IgE
antibodies, several substances can induce histamine
release from human basophils, such as calcium iono-
phore (A23187), thapsigargin, and fMLP. Cell signal-
ing cascades induced by these molecules overlap
considerably with those of FcεRI. For example, fMLP
induces histamine release by activation of PLC and PI
3K via formyl peptide receptor without Syk phospho-
rylation, which is a key reaction in the FcεRI path-
way.24-26 Thapsigargin induced depletion of calcium
in the endoplasmic reticulum and calcium influx
through calcium release-activated calcium chan-
nels.27 We observed no augmentation of histamine re-
lease by aspirin when basophils were activated with A
23218, thapsigargin, or fMLP. Moreover, aspirin aug-
Matsuo H et al.
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Fig.　6　Sensitivity to aspirin induced basophil histamine re-
lease in patients with chronic urticarial and FDEIA. Basophils 
obtained from peripheral blood were incubated with anti-IgE 
and aspirin concentrations of 100 or 1000 μM for 40 min at 
37°C. Augmentation was expressed as a ratio of the net his-
tamine release from basophils in the presence or absence of 
aspirin. Open circle- patients with chronic urticaria; closed 
circle- patients with FDEIA; closed triangle- healthy controls.
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mented histamine release from crude leukocyte
preparations and from purified human basophils, indi-
cating that aspirin can directly influence basophils.
Gibbs et al.22 reported that Syk phosphorylation in
human basophils by anti-IgE stimulation lasted for 10
minutes after stimulation and decreased after 15 min.
Based on this result, we analyzed Syk phosphoryla-
tion 10 minutes after stimulation in purified basophils
and found that phosphorylation of Tyr352 in Syk was
markedly increased by aspirin. These results suggest
that aspirin acts upstream of Syk kinase in the FcεRI
receptor signaling cascade. Aspirin inhibited hista-
mine release induced by A23187, thapsigargin, and
fMLP whereas it augmented histamine release by
anti-IgE stimuli in human basophils, indicating that
aspirin may also act as an inhibitor of the histamine
release pathway following calcium influx.
Although histamine release from human basophils
is augmented by aspirin, aspirin inhibits histamine re-
lease from rat RBL-2H3 cells, rat peritoneal mast
cells,28-30 and mouse bone marrow derived mast
cells.19 We confirmed that aspirin inhibits histamine-
release-induced antigen in rat RBL-2H3 cells (data
not shown). Siraganian et al.31 reported that following
PTEN phosphatase gene inhibition, degranulation in
a MMC-1 mouse mast cell line was inhibited, but en-
hanced in bone marrow derived mast cells. This op-
posite effect may be explained by a subtle difference
in the balance between PIP2 and PIP3 in the cell. The
difference in the effects of aspirin between human ba-
sophils and rat RBL-2H3 or mast cells may be ex-
plained by the balance of signaling pathways includ-
ing PIP2 and PIP3 in these cells.
In summary, aspirin enhances histamine release
from human basophils via Sky kinase activation in vi-
tro and the effect is specific to histamine release in-
duced by FcεRI receptor stimulation. This may be a
cause of the aggravation of urticaria by aspirin. In
fact, the increased sensitivity to aspirin was seen in a
certain population of patients and healthy subjects at
a dose of 1000 μM, but more dominantly in patients at
100 μM (Fig. 6). Siebert DJ et al.32 reported that tak-
ing 600 mg of aspirin yielded peak plasma aspirin lev-
els of 28 to 56 μM and peak salicylate, a main metabo-
lite of aspirin, levels of 72 to 290 μM. Their results in-
dicate that plasma concentration of aspirin cannot
reach 100 μM at conventional aspirin dose. However,
we speculated that local high concentration of aspirin
in intestinal tract right after taking the medication,
and salicylate that augments histamine release as
well as aspirin can contribute to aggravation of urti-
caria in patients. On the other hand, it has been re-
ported recently that exacerbation of allergic symp-
toms by aspirin in patients with FDEIA is not medi-
ated by the direct effects of aspirin on mast cells or
basophils.33 Thus, further studies are required to
clarify the relationship between the basophil or mast
cell activation by aspirin and salicylate in vitro and
the exacerbation of clinical symptoms.
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